The data set for this report shows data for the months January-March 2026, as of 31 March 2026, as well as cumulative numbers since the launch of CTIS on 31 January 2022. According to Article 98 of the Clinical Trials Regulation (EU) 536/2014, the transition period finished the 30 January 2025.
The European Commission (EC), the Heads of Medicines Agencies (HMA) and EMA have published their first report tracking progress against the EU’s new clinical trial targets. Established in 2025, these targets aim to strengthen the European Union’s (EU) position as a leading destination for clinical research while improving patients’ timely access to innovative medicines.
Covering activity from 1 January 2026 to the end of March 2026, the report highlights early progress towards these ambitions:
- Increase in multinational trials: 19 multinational clinical trials have been authorised in addition to the historical average, bringing the EU closer to its goal of 500 extra multinational trials by the end of 2030.
- Faster recruitment timelines: currently, 40.5% of the total number of clinical trials recruit participants within 200 days from application submission. The EU target is 66% by 2030.